NCT02976142Unknown2 期
Prospective Randomized Phase II Clinical Trial: the Efficacy of Surgical Treatment in Combinations With Intraperitoneal Immunotherapy and Systemic Chemotherapy in Patients With Gastric Cancer and Verified Free Cancer Cells
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 150
- 主要终点
- Overall 2-year survival
研究概览
简要总结
The purpose of this study is to determine whether intraperitoneal immunotherapy (with interleykin-2 - human cytokine reaction activator) with systemic chemotherapy will be more effective than systemic chemotherapy alone in patients with gastric cancer and verified free cancer cells in abdominal cavity in improving the long term outcomes and overall survival of further surgical treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven gastric cancer T2-3 N+, T4a with any N (0,+) with free cancer cells in the abdominal cavity and no macroscopic canceromathosis and no other distant metastases (TNM classification 7th edition)
- •Histological forms: gastric adenocarcinoma and signet ring cancer
- •Blood characteristics (creatinine <150 mg/l, total bilirubin < 50 mkmol/l, neutrophils < 1500/mkl, hemoglobin >90 g/l, thrombocytes > 100000/mkl)
排除标准
- •Clinically apparent distant metastasis (besides free cancer cells)
- •Synchronic or metachronic malignant tumors
- •Previous systemic or surgical or combined therapy for gastric cancer
- •Complications of gastric cancer (obstruction 0-1 GOOSS scale and/or gastric bleeding)
- •Adhesions in abdominal cavity
- •Gastrooesophageal junction cancer or gastric cancer with spreading on oesophagus.
结局指标
主要结局
Overall 2-year survival
时间窗: 2 years
Overall 2-year survival for patients who received radical (R0) surgical treatment after downstaging (M1 -\> M0; Cyt "+" -\> Cyt "-") with initial free cancer cells in the abdominal cavity without macroscopic canceromathosis.
次要结局
- Mortality(24 months)
- Portability of the systemic therapy methods(6,9,12,24 months)
- Downstaging tumor(2 years)
- Quality of life(6, 12, 18, 24 months)
- Morbidity(30 days)
研究者
相似试验
已完成
2 期
Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal CancerPrimary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerNCT00016289National Cancer Institute (NCI)30
已完成
2 期
A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV TherapyHIV InfectionsNCT00000909National Institute of Allergy and Infectious Diseases (NIAID)36
招募中
2 期
Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous DiseaseHigh-Risk Oral Precancerous DiseaseNCT06623110Glenn J. Hanna25
已完成
1 期
Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune SystemsHIV InfectionsNCT00006066National Institute of Allergy and Infectious Diseases (NIAID)92
终止
2 期
Interleukin-2 in Metastatic Kidney CancerRenal Cell Cancer MetastaticKidney Cancer MetastaticNCT01702909Western Regional Medical Center7